Cargando…

1429. Emergence of Multidrug-resistant Serotype 24 Among Children Under 2 Years Old With Invasive Pneumococcal Disease After the Introduction of PCV13 in Argentina

BACKGROUND: In Argentina PCV13 was included in the National Vaccination Program in January 2012 for children <2 years old Since 1993 S. pneumoniae Surveillance Program (SIREVA II-OPS/WHO) was conducted in the National Reference Laboratory (NRL). Serotype 24 rarely found before 2012, emerged after...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagetti, Paula, Menocal, Alejandra, Faccone, Diego, Fossati, Sofia, Napoli, Daniela, Regueira, Mabel, Corso, Alejandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253465/
http://dx.doi.org/10.1093/ofid/ofy210.1260
Descripción
Sumario:BACKGROUND: In Argentina PCV13 was included in the National Vaccination Program in January 2012 for children <2 years old Since 1993 S. pneumoniae Surveillance Program (SIREVA II-OPS/WHO) was conducted in the National Reference Laboratory (NRL). Serotype 24 rarely found before 2012, emerged after the introduction of PCV13. We aimed to analyze the trend in serotype 24 distribution and its associated resistance in children <2 years old between 2010 and 2016. METHODS: A total of 1,821 Spn isolates (<6 years old) from sterile fluids were received at NRL between January 2010 and December 2016 from 150 hospitals, 24 provinces and Buenos Aires city; 1029 (56.5%) <2 years old. Isolates were serotyped by Quellung, MICs were performed by agar dilution (CLSI) and resistance genes by PCR. Diagnosis: pneumonia (42%), meningitis (28%), sepsis (16%), other (14%). Eighty of 1,029 (7.8%) Spn were serotype 24. Three periods were defined: pre-PCV13 (2010–2011), transitional (2012) and post-PCV13 (2013–2016). RESULTS: Among 1,029 Spn isolated in <2 years old, PCV13 serotypes decreased from 86.4% (pre-PCV13) to 33.7% (post-PCV13) related to serotypes: 14, 6A, 6B and 5 (P < 0.05). Non-PCV13 serotypes increased from 13.6% (pre-PCV13) to 66.3%% (post-PCV13), mainly due to serotypes 24, 12F and 23B (P < 0.05). Among 80 serotype 24 Spn, 44 (55%) were <1 years old. Serotype 24 increased from 2.1 to 16.2% (pre-/post-PCV13), and ranks first since 2013. Antimicrobial nonsusceptibility (NS) among serotype 24 in pre-/post-PCV13 periods was: penicillin (PEN) (MIC ≥0.12 µg/mL) 70/91.2%, cefotaxime (MIC ≥ 1 µg/mL) 0/1.5%, erythromycin (ERY) 70/89.7%, tetracycline (TET) 60/83.8% and trimethoprim-sulfamethoxazole (SXT) 60/89.7%. NS to meropenem, chloramphenicol, levofloxacin, rifampicin, ceftaroline, and vancomycin was no detected. 97.1% of ERY-NS isolates carried ermB and 2.9% mefA genes. All the TET-NS isolates carried the tetM gene. Multidrug resistance to PEN, ERY, TET, and SXT increased from 50% in pre-PCV13 to 82% in post-PCV13 period (P < 0.05). CONCLUSION: Serotype 24 represents the main non-PCV13 serotype in <2 years old with IPD after the introduction of PCV13. We observed an increase in prevalence and multidrug resistance in post-PCV13 period. Our results suggest that this emerging serotype could represent a real threat among pneumococcal disease in the near future. DISCLOSURES: All authors: No reported disclosures.